signal/raiseTrack rounds
Pre-seedHealthtech & bio · Helsinki

Switchpoint Bio raises $5.3m pre-seed to track treatment response from blood samples

Treehouse Delmar Investments put in $5m of the round for the Helsinki and Cambridge startup, whose founders include the CEO and CTO of Blueprint Genetics and ATAC-seq inventor Jason Buenrostro.

s/rFunding deskEurope · 2 min read

Switchpoint Bio, a startup that reads changes in patients' immune cells from blood samples, raised $5.3m in pre-seed funding as it came out of stealth, it announced on 10 November 2026.

Treehouse Delmar Investments provided $5m of the round. No other investors were named, and the company did not disclose a valuation. Switchpoint Bio has teams in Helsinki and in Cambridge, Massachusetts.

“Drug developers need to know not only whether a patient responds, but what biology changed, what persisted and why”Samuel Myllykangas, PhD, co-founder and CEO, Switchpoint Bio

What Switchpoint Bio does

Drug developers often cannot see why some patients respond to a treatment and others do not. Tracking the underlying biology usually means repeated tissue biopsies, or single-cell analysis, which needs fresh samples and specialised lab work.

Switchpoint Bio measures DNA methylation, chemical marks that switch genes on and off, in immune cells circulating in the blood. It focuses on regions of the genome that are active in disease and immune biology and uses AI to interpret the results, drawing on single-cell reference data and population-scale datasets. The aim is to show from a routine blood draw, taken again and again during treatment, how a disease and a drug are changing the patient's biology.

The company is testing the method first in autoimmune disease, including systemic lupus erythematosus, where it is tracking immune states through treatment. It has not announced any commercial partnerships but says it is in talks with pharmaceutical and biotech companies about first industry validation programmes, with treatment response as a central focus.

The team

Chief executive Samuel Myllykangas previously built and scaled Blueprint Genetics, a genetic diagnostics company acquired by Quest Diagnostics in 2020, and before that worked on sequencing technology at Stanford. Chief technology officer Jussi Paananen was Blueprint Genetics' CTO.

Co-founder Jason Buenrostro, a Harvard professor and director of the Epigenomics Program at the Broad Institute, invented ATAC-seq, a widely used method for mapping open regions of DNA. He worked with Myllykangas at Stanford and later received a MacArthur Fellowship. In a post on the company's origins, Myllykangas recalled the two of them asking what would become possible if human biology could be read with a precision and scale that had not existed before. He wrote that biology leaves a record in blood, and that the company was founded to learn how to read it. Chief commercial officer Niilo Färkkilä previously worked at Amgen and GSK, and Mitja Kurki brings experience from FinnGen, a Finnish genetic study of more than 500,000 people. The company did not disclose its headcount or founding date.

What the money is for

Switchpoint Bio said it will use the funding for clinical and industry validation, to add clinical and biobank data, to develop its epigenomic and AI platform and to hire scientific and technical staff in Helsinki and Cambridge.

Dave Proctor of Treehouse Delmar Investments said the firm takes a long-term view and backs science it believes can change how disease is understood and treated. Myllykangas said the company's goal is to make these biological changes visible from a routine blood sample at the scale drug development requires.

Company website: switchpointbio.com